Global Human Microbiome Therapeutics Market Size Study, by Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs), by Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders, Infectious Disease, Metabolic Disorders, Oncology, Others), by Indication (Acne Vulgaris, Atopic Dermatitis, Clostridium difficile Infection, Colorectal Cancer, Diabetes, Inflammatory Bowel Disease (IBD), Lactose Intolerance, Lung Cancer, Non-alcoholic steatohepatitis (NASH), Obesity, Coeliac Disease), by Approach (Small Molecule Therapies, Single Strain Whole Bacteria, Microbial Consortia, Genetically Modified Single Strain Bacteria, Phage Cocktail, Microbial Ecosystems) and Regional Forecasts 2022-2032
The Global Human Microbiome Therapeutics Market is valued at approximately USD 624.17 million in 2023 and is anticipated to grow with a healthy growth rate of more than 22.7% over the forecast period 2024-2032. Human Microbiome Therapeutics refers to a branch of medicine focused on developing treatments that target the human microbiome—the diverse community of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit various parts of the body, particularly the gut. These therapeutics aim to restore or modify the microbiome to improve health and treat diseases. This can involve the use of probiotics (beneficial bacteria), prebiotics (compounds that promote the growth of beneficial bacteria), postbiotics (metabolites produced by probiotic bacteria), and fecal microbiota transplantation (FMT). Human Microbiome Therapeutics is being explored for a wide range of conditions, including gastrointestinal disorders like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), metabolic disorders such as obesity and diabetes, and even neurological conditions and cancer. By targeting the microbiome, these therapies hold promise for personalized medicine approaches, offering treatments tailored to the unique microbial composition of an individual's body.
Human microbiome therapeutics encompass products or interventions that aim to modulate the microbiome's composition or activity to promote health or treat diseases. These include probiotics, prebiotics, fecal microbiota transplantation (FMT), and other microbiome-based therapies. Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts. Prebiotics selectively stimulate the growth or activity of beneficial organisms in the gut. FMT involves the transfer of fecal matter from a healthy donor to a recipient to restore a balanced microbiome. Key growth drivers include the rising incidence of diseases related to dysbiosis in the gut microbiota and substantial funding for biological drug discovery and research. The market also benefits from the granting of orphan drug designations and advanced treatment designations for human microbiome therapies, which are expected to accelerate the introduction of new pharmaceuticals. However, long regulatory pathways and high development costs would stifle the market growth.
Key regions considered for the Global Human Microbiome Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East and Afirca. North America dominated the market in 2022, driven by robust investments in research and development, a strong regulatory framework, and a high prevalence of chronic diseases. The region benefits from a well-established healthcare infrastructure, leading academic and research institutions, and substantial funding from both government and private sectors. Furthermore, the presence of key industry players and advanced biotechnology capabilities contribute to North America's market leadership. The Asia Pacific region is expected to grow rapidly in the coming years, owing to several factors. The increasing elderly population in countries like Japan and China leads to a higher demand for healthcare services, including innovative treatments such as microbiome therapeutics. Additionally, the rising incidence of chronic diseases such as diabetes, cardiovascular diseases, and gastrointestinal disorders drives the need for new and effective therapeutic options. Improvements in healthcare infrastructure, growing awareness of microbiome-based treatments, and increasing investments in biotechnology and pharmaceutical research also support the rapid growth of the Human Microbiome Therapeutics Market in the Asia Pacific region.
Major market players included in this report are:
Seres Therapeutics, Inc.
Aobiome LLC
Synlogic, Inc.
Enterome Bioscience SA
Mighty Microbes Inc.
Evelo Biosciences, Inc.
Ferring Pharmaceuticals Inc.
Osel, Inc.
Vedanta Biosciences, Inc.
Rebiotix Inc. (a subsidiary of Ferring Pharmaceuticals)
MediSprout LLC
Ubiome, Inc.
BioCare Copenhagen A/S
Bacterioides Therapeutics Inc.
Phio Pharmaceuticals Corp.
The detailed segments and sub-segment of the market are explained below:
By Product:
Probiotics
Prebiotics
Medical Foods
Prescription Drugs
By Therapeutic Area:
Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Oncology
Others
By Indication:
Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Diabetes
Inflammatory Bowel Disease (IBD)
Lactose Intolerance
Lung Cancer
Non-alcoholic steatohepatitis (NASH)
Obesity
Coeliac Disease
By Approach:
Small Molecule Therapies
Single Strain Whole Bacteria
Microbial Consortia
Genetically Modified Single Strain Bacteria
Phage Cocktail
Microbial Ecosystems
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
Human microbiome therapeutics encompass products or interventions that aim to modulate the microbiome's composition or activity to promote health or treat diseases. These include probiotics, prebiotics, fecal microbiota transplantation (FMT), and other microbiome-based therapies. Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts. Prebiotics selectively stimulate the growth or activity of beneficial organisms in the gut. FMT involves the transfer of fecal matter from a healthy donor to a recipient to restore a balanced microbiome. Key growth drivers include the rising incidence of diseases related to dysbiosis in the gut microbiota and substantial funding for biological drug discovery and research. The market also benefits from the granting of orphan drug designations and advanced treatment designations for human microbiome therapies, which are expected to accelerate the introduction of new pharmaceuticals. However, long regulatory pathways and high development costs would stifle the market growth.
Key regions considered for the Global Human Microbiome Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East and Afirca. North America dominated the market in 2022, driven by robust investments in research and development, a strong regulatory framework, and a high prevalence of chronic diseases. The region benefits from a well-established healthcare infrastructure, leading academic and research institutions, and substantial funding from both government and private sectors. Furthermore, the presence of key industry players and advanced biotechnology capabilities contribute to North America's market leadership. The Asia Pacific region is expected to grow rapidly in the coming years, owing to several factors. The increasing elderly population in countries like Japan and China leads to a higher demand for healthcare services, including innovative treatments such as microbiome therapeutics. Additionally, the rising incidence of chronic diseases such as diabetes, cardiovascular diseases, and gastrointestinal disorders drives the need for new and effective therapeutic options. Improvements in healthcare infrastructure, growing awareness of microbiome-based treatments, and increasing investments in biotechnology and pharmaceutical research also support the rapid growth of the Human Microbiome Therapeutics Market in the Asia Pacific region.
Major market players included in this report are:
Seres Therapeutics, Inc.
Aobiome LLC
Synlogic, Inc.
Enterome Bioscience SA
Mighty Microbes Inc.
Evelo Biosciences, Inc.
Ferring Pharmaceuticals Inc.
Osel, Inc.
Vedanta Biosciences, Inc.
Rebiotix Inc. (a subsidiary of Ferring Pharmaceuticals)
MediSprout LLC
Ubiome, Inc.
BioCare Copenhagen A/S
Bacterioides Therapeutics Inc.
Phio Pharmaceuticals Corp.
The detailed segments and sub-segment of the market are explained below:
By Product:
Probiotics
Prebiotics
Medical Foods
Prescription Drugs
By Therapeutic Area:
Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Oncology
Others
By Indication:
Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Diabetes
Inflammatory Bowel Disease (IBD)
Lactose Intolerance
Lung Cancer
Non-alcoholic steatohepatitis (NASH)
Obesity
Coeliac Disease
By Approach:
Small Molecule Therapies
Single Strain Whole Bacteria
Microbial Consortia
Genetically Modified Single Strain Bacteria
Phage Cocktail
Microbial Ecosystems
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET EXECUTIVE SUMMARY
1.1. Global Human Microbiome Therapeutics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Therapeutic Area
1.3.3. By Indication
1.3.4. By Approach
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Prevalence of Conditions Related to Dysbiosis
3.1.2. Advancements in Sequencing Technologies and Bioinformatics
3.1.3. Regulatory Support for Microbiome-Based Therapeutics
3.2. Market Challenges
3.2.1. Long Regulatory Pathways
3.2.2. High Development Costs
3.3. Market Opportunities
3.3.1. Growing Clinical Trials for Microbiome-Based Therapies
3.3.2. Increasing Investment in Microbiome Research
CHAPTER 4. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY PRODUCT 2022-2032
5.1. Segment Dashboard
5.2. Global Human Microbiome Therapeutics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Probiotics
5.2.2. Prebiotics
5.2.3. Medical Foods
5.2.4. Prescription Drugs
CHAPTER 6. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY THERAPEUTIC AREA 2022-2032
6.1. Segment Dashboard
6.2. Global Human Microbiome Therapeutics Market: Therapeutic Area Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Autoimmune Disorders
6.2.2. Dental Disorders
6.2.3. Digestive and Gastrointestinal Disorders
6.2.4. Dermatological Disorders
6.2.5. Infectious Disease
6.2.6. Metabolic Disorders
6.2.7. Oncology
6.2.8. Others
CHAPTER 7. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY INDICATION 2022-2032
7.1. Segment Dashboard
7.2. Global Human Microbiome Therapeutics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Acne Vulgaris
7.2.2. Atopic Dermatitis
7.2.3. Clostridium difficile Infection
7.2.4. Colorectal Cancer
7.2.5. Diabetes
7.2.6. Inflammatory Bowel Disease (IBD)
7.2.7. Lactose Intolerance
7.2.8. Lung Cancer
7.2.9. Non-alcoholic steatohepatitis (NASH)
7.2.10. Obesity
7.2.11. Coeliac Disease
CHAPTER 8. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY APPROACH 2022-2032
8.1. Segment Dashboard
8.2. Global Human Microbiome Therapeutics Market: Approach Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.2.1. Small Molecule Therapies
8.2.2. Single Strain Whole Bacteria
8.2.3. Microbial Consortia
8.2.4. Genetically Modified Single Strain Bacteria
8.2.5. Phage Cocktail
8.2.6. Microbial Ecosystems
CHAPTER 9. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032
9.1. North America Human Microbiome Therapeutics Market
9.1.1. U.S. Human Microbiome Therapeutics Market
9.1.1.1. Site breakdown size & forecasts, 2022-2032
9.1.1.2. Application breakdown size & forecasts, 2022-2032
9.1.1.3. Disease breakdown size & forecasts, 2022-2032
9.1.1.4. Product breakdown size & forecasts, 2022-2032
9.1.2. Canada Human Microbiome Therapeutics Market
9.2. Europe Human Microbiome Therapeutics Market
9.2.1. UK Human Microbiome Therapeutics Market
9.2.2. Germany Human Microbiome Therapeutics Market
9.2.3. France Human Microbiome Therapeutics Market
9.2.4. Italy Human Microbiome Therapeutics Market
9.2.6. Spain Human Microbiome Therapeutics Market
9.2.8. Rest of Europe Human Microbiome Therapeutics Market
9.3. Asia-Pacific Human Microbiome Therapeutics Market
9.3.1. China Human Microbiome Therapeutics Market
9.3.2. India Human Microbiome Therapeutics Market
9.3.3. Japan Human Microbiome Therapeutics Market
9.3.4. Australia Human Microbiome Therapeutics Market
9.3.5. South Korea Human Microbiome Therapeutics Market
9.3.7. Rest of Asia Pacific Human Microbiome Therapeutics Market
9.4. Latin America Human Microbiome Therapeutics Market
9.4.1. Brazil Human Microbiome Therapeutics Market
9.4.2. Mexico Human Microbiome Therapeutics Market
9.4.3. Rest of Latin America Human Microbiome Therapeutics Market
9.5. Middle East & Africa Human Microbiome Therapeutics Market
9.5.1. Saudi Arabia Human Microbiome Therapeutics Market
9.5.3. South Africa Human Microbiome Therapeutics Market
9.5.5. Rest of Middle East & Africa Human Microbiome Therapeutics Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Company
10.1.2. Company
10.1.3. Company
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Seres Therapeutics, Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Aobiome LLC
10.3.3 Synlogic, Inc.
10.3.4. Enterome Bioscience SA
10.3.5. Mighty Microbes Inc.
10.3.6. Evelo Biosciences, Inc.
10.3.7. Ferring Pharmaceuticals Inc.
10.3.8. Osel, Inc.
10.3.9. Vedanta Biosciences, Inc.
10.3.10. Rebiotix Inc. (a subsidiary of Ferring Pharmaceuticals)
10.3.11. MediSprout LLC
10.3.12. Ubiome, Inc.
10.3.13. BioCare Copenhagen A/S
10.3.14. Bacterioides Therapeutics Inc.
10.3.15. Phio Pharmaceuticals Corp.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
1.1. Global Human Microbiome Therapeutics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Therapeutic Area
1.3.3. By Indication
1.3.4. By Approach
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Prevalence of Conditions Related to Dysbiosis
3.1.2. Advancements in Sequencing Technologies and Bioinformatics
3.1.3. Regulatory Support for Microbiome-Based Therapeutics
3.2. Market Challenges
3.2.1. Long Regulatory Pathways
3.2.2. High Development Costs
3.3. Market Opportunities
3.3.1. Growing Clinical Trials for Microbiome-Based Therapies
3.3.2. Increasing Investment in Microbiome Research
CHAPTER 4. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY PRODUCT 2022-2032
5.1. Segment Dashboard
5.2. Global Human Microbiome Therapeutics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Probiotics
5.2.2. Prebiotics
5.2.3. Medical Foods
5.2.4. Prescription Drugs
CHAPTER 6. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY THERAPEUTIC AREA 2022-2032
6.1. Segment Dashboard
6.2. Global Human Microbiome Therapeutics Market: Therapeutic Area Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Autoimmune Disorders
6.2.2. Dental Disorders
6.2.3. Digestive and Gastrointestinal Disorders
6.2.4. Dermatological Disorders
6.2.5. Infectious Disease
6.2.6. Metabolic Disorders
6.2.7. Oncology
6.2.8. Others
CHAPTER 7. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY INDICATION 2022-2032
7.1. Segment Dashboard
7.2. Global Human Microbiome Therapeutics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Acne Vulgaris
7.2.2. Atopic Dermatitis
7.2.3. Clostridium difficile Infection
7.2.4. Colorectal Cancer
7.2.5. Diabetes
7.2.6. Inflammatory Bowel Disease (IBD)
7.2.7. Lactose Intolerance
7.2.8. Lung Cancer
7.2.9. Non-alcoholic steatohepatitis (NASH)
7.2.10. Obesity
7.2.11. Coeliac Disease
CHAPTER 8. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY APPROACH 2022-2032
8.1. Segment Dashboard
8.2. Global Human Microbiome Therapeutics Market: Approach Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.2.1. Small Molecule Therapies
8.2.2. Single Strain Whole Bacteria
8.2.3. Microbial Consortia
8.2.4. Genetically Modified Single Strain Bacteria
8.2.5. Phage Cocktail
8.2.6. Microbial Ecosystems
CHAPTER 9. GLOBAL HUMAN MICROBIOME THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032
9.1. North America Human Microbiome Therapeutics Market
9.1.1. U.S. Human Microbiome Therapeutics Market
9.1.1.1. Site breakdown size & forecasts, 2022-2032
9.1.1.2. Application breakdown size & forecasts, 2022-2032
9.1.1.3. Disease breakdown size & forecasts, 2022-2032
9.1.1.4. Product breakdown size & forecasts, 2022-2032
9.1.2. Canada Human Microbiome Therapeutics Market
9.2. Europe Human Microbiome Therapeutics Market
9.2.1. UK Human Microbiome Therapeutics Market
9.2.2. Germany Human Microbiome Therapeutics Market
9.2.3. France Human Microbiome Therapeutics Market
9.2.4. Italy Human Microbiome Therapeutics Market
9.2.6. Spain Human Microbiome Therapeutics Market
9.2.8. Rest of Europe Human Microbiome Therapeutics Market
9.3. Asia-Pacific Human Microbiome Therapeutics Market
9.3.1. China Human Microbiome Therapeutics Market
9.3.2. India Human Microbiome Therapeutics Market
9.3.3. Japan Human Microbiome Therapeutics Market
9.3.4. Australia Human Microbiome Therapeutics Market
9.3.5. South Korea Human Microbiome Therapeutics Market
9.3.7. Rest of Asia Pacific Human Microbiome Therapeutics Market
9.4. Latin America Human Microbiome Therapeutics Market
9.4.1. Brazil Human Microbiome Therapeutics Market
9.4.2. Mexico Human Microbiome Therapeutics Market
9.4.3. Rest of Latin America Human Microbiome Therapeutics Market
9.5. Middle East & Africa Human Microbiome Therapeutics Market
9.5.1. Saudi Arabia Human Microbiome Therapeutics Market
9.5.3. South Africa Human Microbiome Therapeutics Market
9.5.5. Rest of Middle East & Africa Human Microbiome Therapeutics Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Company
10.1.2. Company
10.1.3. Company
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Seres Therapeutics, Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Aobiome LLC
10.3.3 Synlogic, Inc.
10.3.4. Enterome Bioscience SA
10.3.5. Mighty Microbes Inc.
10.3.6. Evelo Biosciences, Inc.
10.3.7. Ferring Pharmaceuticals Inc.
10.3.8. Osel, Inc.
10.3.9. Vedanta Biosciences, Inc.
10.3.10. Rebiotix Inc. (a subsidiary of Ferring Pharmaceuticals)
10.3.11. MediSprout LLC
10.3.12. Ubiome, Inc.
10.3.13. BioCare Copenhagen A/S
10.3.14. Bacterioides Therapeutics Inc.
10.3.15. Phio Pharmaceuticals Corp.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Human Microbiome Therapeutics market, report scope
TABLE 2. Global Human Microbiome Therapeutics market estimates & forecasts by Region 2022-2032 (USD Million)
TABLE 3. Global Human Microbiome Therapeutics market estimates & forecasts by Product 2022-2032 (USD Million)
TABLE 4. Global Human Microbiome Therapeutics market estimates & forecasts by Therapeutic Area 2022-2032 (USD Million)
TABLE 5. Global Human Microbiome Therapeutics market estimates & forecasts by Indication 2022-2032 (USD Million)
TABLE 6. Global Human Microbiome Therapeutics market estimates & forecasts by Approach 2022-2032 (USD Million)
TABLE 7. U.S. Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 8. U.S. Human Microbiome Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 9. Canada Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 10. Canada Human Microbiome Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 11. UK Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 12. Germany Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 13. France Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 14. Italy Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 15. Netherlands Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 16. Spain Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 17. Russia Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 18. China Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 19. India Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 20. Japan Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.
TABLE 1. Global Human Microbiome Therapeutics market, report scope
TABLE 2. Global Human Microbiome Therapeutics market estimates & forecasts by Region 2022-2032 (USD Million)
TABLE 3. Global Human Microbiome Therapeutics market estimates & forecasts by Product 2022-2032 (USD Million)
TABLE 4. Global Human Microbiome Therapeutics market estimates & forecasts by Therapeutic Area 2022-2032 (USD Million)
TABLE 5. Global Human Microbiome Therapeutics market estimates & forecasts by Indication 2022-2032 (USD Million)
TABLE 6. Global Human Microbiome Therapeutics market estimates & forecasts by Approach 2022-2032 (USD Million)
TABLE 7. U.S. Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 8. U.S. Human Microbiome Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 9. Canada Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 10. Canada Human Microbiome Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 11. UK Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 12. Germany Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 13. France Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 14. Italy Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 15. Netherlands Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 16. Spain Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 17. Russia Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 18. China Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 19. India Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 20. Japan Human Microbiome Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.
LIST OF FIGURES
FIG 1. Global Human Microbiome Therapeutics market, research methodology
FIG 2. Global Human Microbiome Therapeutics market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Human Microbiome Therapeutics market, key trends 2023
FIG 5. Global Human Microbiome Therapeutics market, growth prospects 2022-2032
FIG 6. Global Human Microbiome Therapeutics market, porters 5 force model
FIG 7. Global Human Microbiome Therapeutics market, PESTEL analysis
FIG 8. Global Human Microbiome Therapeutics market, value chain analysis
FIG 9. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 10. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 11. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 12. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 13. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 14. Global Human Microbiome Therapeutics market, regional snapshot 2022 & 2032
FIG 15. North America Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 16. Europe Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 17. Asia-Pacific Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 18. Latin America Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 19. Middle East & Africa Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 20. Global Human Microbiome Therapeutics market, company market share analysis (2023)
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.
FIG 1. Global Human Microbiome Therapeutics market, research methodology
FIG 2. Global Human Microbiome Therapeutics market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Human Microbiome Therapeutics market, key trends 2023
FIG 5. Global Human Microbiome Therapeutics market, growth prospects 2022-2032
FIG 6. Global Human Microbiome Therapeutics market, porters 5 force model
FIG 7. Global Human Microbiome Therapeutics market, PESTEL analysis
FIG 8. Global Human Microbiome Therapeutics market, value chain analysis
FIG 9. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 10. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 11. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 12. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 13. Global Human Microbiome Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 14. Global Human Microbiome Therapeutics market, regional snapshot 2022 & 2032
FIG 15. North America Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 16. Europe Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 17. Asia-Pacific Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 18. Latin America Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 19. Middle East & Africa Human Microbiome Therapeutics market 2022 & 2032 (USD Million)
FIG 20. Global Human Microbiome Therapeutics market, company market share analysis (2023)
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.
